Why Making Dramatic Moves: Xenon Pharmaceuticals Inc. (NASDAQ:XENE), The Phoenix Companies (NYSE:PNX), Tupperware Brands (NYSE:TUP), Air Industries Group (NYSEMKT:AIRI), Idera Pharmaceuticals (NASDAQ:IDRA)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) reported its financial results for the quarter ended June 30, 2015 and provided a corporate update. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) belongs to Healthcare sector. Its net profit margin is 27.20% and weekly performance is -12.76%. On last trading day company shares ended up $9.16. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) distance from 50-day simple moving average (SMA50) is -19.59%.

The Phoenix Companies Inc. (NYSE:PNX) announced financial results for the second quarter of 2015 and filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 with the U.S. Securities and Exchange Commission (“SEC”). The Phoenix Companies Inc. (NYSE:PNX) shares fell -3.95% in last trading session and ended the day at $12.63. Its return on assets is -1.20%. The Phoenix Companies Inc. (NYSE:PNX) quarterly performance is -41.55%.

Tupperware Brands Corporation (NYSE:TUP) most recently announced a dividend payout of $0.68 per share to shareholders of record on 2015-06-18, payable on 2015-07-06. This was announced publicly to investors on 2015-05-08. The Ex-Dividend date, which is often the most important to investors, would be 2015-06-16. Shareholders would need to own the stock before this date in order to receive the dividend payout. On 11 August, Tupperware Brands Corporation (NYSE:TUP) shares fell -3.64% and was closed at $55.63. TUP EPS growth in last 5 year was 8.80%. Tupperware Brands Corporation (NYSE:TUP) year to date (YTD) performance is -9.85%.

Air Industries Group (NYSEMKT:AIRI) reports financial results for the three and six months ended June 30, 2015. We remain on plan to deliver on our guidance of revenue and EBITDA for 2015 of $85 to $95 million and $10 to $13 million respectively” said Dan Godin, Chief Executive Officer of Air Industries Group, who continued, “Our second quarter net sales results reflect the contribution of four acquisitions completed in the second half of 2014 and the first quarter of 2015. We are very happy to report that our “legacy businesses” showed their first occurrence of a quarter over quarter increase in sales for some time. The increases result from our increased new business development activities and we expect increased gains for the remainder of the year. Air Industries Group (NYSEMKT:AIRI) ended the last trading day at $9.06. Company weekly volatility is calculated as 3.43% and price to cash ratio as 27.40. Air Industries Group (NYSEMKT:AIRI) showed a weekly performance of -0.39%.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) reported its financial and operational results for the second quarter ended June 30, 2015. From a program execution perspective, we’ve continued to make steady progress across the board during the second quarter of 2015,” stated Vincent Milano, Idera’s Chief Executive Officer. “We recently announced our strategic clinical research alliance with MD Anderson, with the first planned study of this alliance evaluating the combination of IMO-2125 (TLR9 agonist) and ipilimumab (an anti-CTLA4 antibody) in melanoma patients. We are targeting commencing this study in the fourth quarter of this year. Our B-cell lymphoma programs with IMO-8400 (TLR7, 8 and 9 antagonist) are advancing, as we are rapidly approaching the release of data from the Waldenström’s macroglobulinemia (WM) trial in the fourth quarter. Also in the second quarter, we began enrolling patients into the first dose cohort in the diffuse large B-cell lymphoma (DLBCL) clinical trial. Our rare disease programs are moving forward nicely, most notably with the initiation of our dermatomyositis Phase 2 study planned for the fourth quarter. Finally, we continue to expect to announce the first two diseases we plan to target with our exciting third generation antisense platform technology, which was previously referred to as our GSO program, by the end of this year. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares fell -2.17% in last trading session and ended the day at $2.71. Its return on assets is -54.70%. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) quarterly performance is -10.26%.

Leave a Reply

Your email address will not be published. Required fields are marked *